CELC Stock: $2.5B Peak Sales if Approved — Buy or Avoid?

Celcuity ($CELC) has built a high-stakes biotech story around a targeted breast cancer drug and a predictive diagnostic platform meant to find the patients most likely to benefit. Their lead candidate, gedatolisib, delivered positive Phase 3 results and earned an FDA Priority Review, with a PDUFA decision set for July 17, 2026 — a true make-or-break moment. The company is pre-revenue and essentially a one-drug bet, racing to scale a commercial organization while fending off entrenched oncology giants and managing a finite cash runway. Is this a focused precision-medicine sleeper with blockbuster upside, or a concentrated risk that could unravel if the regulatory or commercial math doesn’t pan out?This podcast is for informational and educational purposes only. Information may not be complete or accurate. It does not constitute financial, investment, legal, or other professional advice. Always do your own research and consult with a licensed financial advisor.And don't forget, you can suggest the tickers you're interested in at www.the5minuteticker.com.